Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. multidiag

MultiDiag

Rapid, cost-effective, multiplex point of care diagnostic immunoassay system

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 MultiDiag project word cloud

Explore the words cloud of the MultiDiag project. It provides you a very rough idea of what is the project "MultiDiag" about.

commercial    quantitative    market    facilities    pricing    route    whilst    opportunity    liquid    modern    standard    globally    plan    diagnostic    diagnoses    mainstay    commercialise    data    cartridge    mean    elisa    sensitivity    disease    oncology    disorders    device    changed    contrast    multiplex    dramatically    hours    parallel    assesses    biomarker    provides    time    series    intend    retaining    inherent    followed    confirm    decades    tested    quantification    size    manufacturable    array    15    point    sensitive    platform    lt    disposable    allergy    biomarkers    tests    laboratory    perform    lined    made    rapid    laboratories    diagnosis    autoimmune    healthcare    near    prepare    panels    infectious    clinical    arrays    care    accurate    takes    stream    incorporated    competition    nalia    multiplexed    reduce    20min    submit    cartridges    central    our    feasibility    diseases    accuracy    benefits    handling    first    patient    complete    initial    immunoassays    accurately    bench    business    earliest   

Project "MultiDiag" data sheet

The following table provides information about the project.

Coordinator		 NALIA SYSTEMS LIMITED 

Organization address
address: C/O DUBOFF & CO, KINGSBURY HOUSE, 468 CHURCH LANE
city: LONDON
postcode: NW9 8UA
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country United Kingdom [UK]
 Project website http://www.naliasystems.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-07-01   to  2015-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    NALIA SYSTEMS LIMITED UK (LONDON) coordinator 50˙000.00

Map

 Project objective

Our overall project is to develop and prepare to commercialise a rapid, cost-effective platform for near-patient diagnosis using multiplex immunoassays. Development of a cost-effective system for diagnosis by multiplex biomarker analysis at the point-of-care is essential to enable the delivery of modern, stream-lined healthcare systems in the EU and globally that rapidly and accurately assesses patient needs at the earliest opportunity. Immunoassays are a mainstay of clinical diagnoses. ELISA tests provide sensitive, accurate and quantitative diagnostic data for a large number of disease biomarkers. The technology has not changed for decades and requires central laboratory facilities. Each test measures only one biomarker and takes up to 2 hours to perform. NALIA Systems’ technology provides multiplexed ELISA tests in which panels of 10-15 biomarkers can be tested in parallel, whilst retaining the sensitivity, accuracy and quantification benefits of standard ELISA tests. The first NALIA Arrays are now being made available for use in laboratories. Standard ELISA technology cannot be adapted for use at point-of-care due to the time to result and the complex liquid handling needed. In contrast, the inherent characteristics of NALIA’s array technology mean that it can be incorporated into disposable cartridges and dramatically reduce the time to result. This project will develop a bench-top device and disposable cartridge system for biomarker arrays for diagnosis at the point of care. Initial arrays will be for autoimmune disorders, allergy and infectious diseases, followed by oncology and other diseases. In Phase 1 we intend to confirm the feasibility of achieving a result in <20min; to prepare a product development plan that will lead to a manufacturable device and series of cartridges; to complete a business plan covering all aspects of the commercial opportunity, pricing, market size, competition and route to market; and submit an application for Phase 2 funding.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MULTIDIAG" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MULTIDIAG" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

INADVANCE (2019)

Patient-centred pathways of early palliative care, supportive ecosystems and appraisal standard

Read More  

PREMSTEM (2020)

Brain injury in the premature born infant: stem cell regeneration research network

Read More  

SHIGETECVAX (2019)

Early clinical development of a live, attenuated combination vaccine against Shigella and ETEC diarrhoea

Read More